Biogen. has filed a patent for a method of lowering elevated cholesterol plasma levels and treating hypercholesterolemia in a subject. The method involves administering an effective amount of Compound 1 or a pharmaceutically acceptable salt, without the use of a cholesterol lowering drug. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of September 2023 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Method of lowering cholesterol levels using compound 1
A recently filed patent (Publication Number: US20230310405A1) describes a method for lowering elevated plasma cholesterol levels in a subject. The method involves administering an effective amount of a compound referred to as Compound 1. This compound can be used to treat subjects with hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood.
The patent claims that Compound 1 can be particularly effective in treating subjects with elevated plasma cholesterol levels associated with various conditions, including familial hypercholesterolemia, atherosclerosis, acute coronary syndrome (ACS), coronary artery disease, peripheral arterial disease (PAD), cerebral vascular disease, diabetes derived cardiovascular diseases, macular degeneration, or congestive heart failure.
In addition to administering Compound 1, the patent also suggests the co-administration of a second pharmaceutically active agent, specifically a cholesterol lowering drug. Examples of such drugs include statins, PCSK9 inhibitors, selective cholesterol absorption inhibitors, bile acid sequestrants, fibrates, or other lipid-lowering therapies.
The patent provides specific dosage ranges for Compound 1, stating that the subject can be administered from 10 mg to 60 mg per day of Compound 1 or an equivalent amount of a pharmaceutically acceptable salt thereof. Furthermore, the patent mentions specific dosage options, including 10 mg/day, 30 mg/day, and 60 mg/day of Compound 1.
Overall, this patent describes a method for lowering elevated plasma cholesterol levels in a subject by administering Compound 1, either alone or in combination with a cholesterol lowering drug. The patent suggests that this method can be effective in treating subjects with hypercholesterolemia and various associated conditions. The specific dosage ranges and options provided in the patent offer guidance for the administration of Compound 1 in clinical practice.
To know more about GlobalData’s detailed insights on Biogen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
